

Filter: Slovakia, minimal size of the groups n = 5

EQA round: KM2/21 - Cardiac Markers

Deadline: 27.08.2021

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability					Comparability							
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}
Set 1														
(218) CK-MB mass					10							8	8	100%
Samples and groups	[µg/L]													
Sample A1		8,40	1,5	17	10							8	8	100%
Other					10	0						8		
							1x 1, 2x 12, 4x 60, 1x 61, 1x 149, 1x 179							
Sample B1		41,8	7,6	18	10							8	8	100%
Other					10	0						8		
							1x 1, 2x 12, 4x 60, 1x 61, 1x 149, 1x 179							
(441) Myoglobin					22							19	19	100%
Samples and groups	[µg/L]													
Sample A1		93,0	9,2	9,9	22							19	19	100%
(60) Roche		94,4	2,9	3,1	13	0	CVPG	94,8	1,1	22%	73,9	116	13	
Other					9	0						6		
							4x 1, 1x 12, 1x 54, 1x 149, 1x 178, 1x 179							
Sample B1		209	34	16	22							19	19	100%
(60) Roche		219	8,9	4,1	13	0	CVPG	220	2,4	22%	171	269	13	
Other					9	0						6		
							2x 1, 2x 843, 1x 12, 1x 54, 1x 149, 1x 178, 1x 179							
(442) Troponin I					13							12	9	75%
Samples and groups	[ng/L]													
Sample A1		2,63	2,3	86	13							12	9	75%
(839) Beckman Coulter UniCel DxI 600, 800		1,65	0,96	58	5	1	CVPG	1,89	0,37	±2,7	0	4,59	5	
Other					8	4						7		
							1x 1/815, 1x 1/821, 2x 2/821, 1x 804, 2x 815, 1x 849							
Sample B1		36,5	30	83	13							12	12	100%
(839) Beckman Coulter UniCel DxI 600, 800		14,0	1,4	10	5	0	CVPG	13,8	0,63	27%	10	17,6	5	
Other					8	0						7		
							1x 1/815, 1x 804, 2x 815, 3x 821, 1x 849							
(443) Troponin T					30							29	24	83%
Samples and groups	[ng/L]													
Sample A1		9,01	2,1	24	30							29	24	83%
(2) Immunochemical methods (hs); (60) Roche		8,97	2,2	25	28	0	CVPG	7,82	0,37	40%	4,69	11	28	
Other					2	0						1		
							1x 1/60, 1x 4/61							
Sample B1		16,1	3,3	21	30							29	28	97%
(2) Immunochemical methods (hs); (60) Roche		16,4	3,1	19	28	0	CVPG	16,2	0,78	40%	9,72	22,7	28	
Other					2	0						1		
							1x 1/60, 1x 4/61							
(444) Homocysteine					22							16	16	100%
Samples and groups	[µmol/L]													
Sample A1		9,74	1,4	14	22							16	16	100%
(109) Axis-Shield		9,95	0,62	6,2	10	0	CVPG	10,1	0,30	26%	7,47	12,8	10	
Other					12	0						6		
							3x 1, 1x 58, 2x 60, 3x 75, 1x 149, 1x 179, 1x 999							
Sample B1		9,30	0,96	10	22							16	16	100%
(109) Axis-Shield		9,40	0,63	6,7	10	0	CVPG	9,48	0,31	26%	7,01	12	10	
Other					12	0						6		
							3x 1, 1x 58, 2x 60, 3x 75, 1x 149, 1x 179, 1x 999							
(447) NT-proBNP					41							38	33	87%
Samples and groups	[ng/L]													
Sample A1		272	31	11	41							38	38	100%
(1) Abbott		272	13	4,7	6	0	CVPG	271	5,9	27%	197	345	6	
(60) Roche		268	24	8,8	27	0	CVPG	263	5,4	27%	191	335	27	
Other					8	0						5		
							2x 15, 3x 54, 2x 61, 1x 149							
Sample B1		61,9	11	18	41							38	33	87%
(1) Abbott		60,1	3,6	5,9	6	0	CVPG	62,7	1,5	27%	45,7	79,7	6	
(60) Roche		63,4	11	17	27	0	CVPG	60,2	2,5	27%	43,9	76,5	27	
Other					8	0						5		
							2x 15, 3x 54, 2x 61, 1x 149							

Test	[unit]						Comparability							
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}
Set 2														
(449) BNP					3							2	2	100%
Samples and groups	[ng/L]													
Sample A2		1610	410	25	3							2	2	100%
Other					3	0						2		
							2x 1, 1x 179							
Sample B2		90,7	36	40	3							2	2	100%
Other					3	0						2		
							2x 1, 1x 179							

st_kn_p

End of report

Printed: 07.09.2021